Safety and effectiveness have not been established in pediatric patients <7 years of age, patients with FEV1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia.
- TRADE NAMES: Azactam (Bristol-Myers Squibb); Cayston (Gilead); Primbactam; Urobactam
- INDICATIONS: Aerobic gram-negative bacillary infections, improve respiratory symptoms in cystic fibrosis patients
- CLASS: Antibiotic, Antibiotic; beta-lactam, Antimicrobial
- HALF-LIFE: 1.4–2.2 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
